MedTrace Logo

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

NCT06869278 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-06-11

No results posted yet for this study

Summary

This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.

Conditions

  • Multiple Sclerosis (MS)
  • Neuromyelitis Optica Spectrum Disease (NMOSD)
  • Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD)
  • Myasthenia Gravis

Interventions

BIOLOGICAL

LCAR-AIO T cells

Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.

Sponsors & Collaborators

  • Nanjing Legend Biotech Co.

    collaborator INDUSTRY

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-17
Primary Completion
2026-06-30
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06869278 on ClinicalTrials.gov